When to Test Testosterone on TRT
Measure testosterone levels 3 to 6 months after starting TRT, then annually thereafter, with timing based on your specific formulation. 1
Initial Monitoring Timeline
The Endocrine Society guidelines provide clear direction: check testosterone levels at 3-6 months after initiation of therapy, then conduct annual monitoring once stable 1. This initial window allows adequate time for steady-state levels to be achieved while catching dose adjustments early enough to prevent adverse effects.
Formulation-Specific Testing Timing
The timing of blood draws matters significantly and varies by formulation 1:
Injectable Testosterone (Enanthate/Cypionate)
- Measure midway between injections (typically day 3-4 of a weekly injection, or day 7 of every-two-week dosing)
- Target range: 400-700 ng/dL (adjust if >700 or <400 ng/dL)
- This captures the steady-state trough-to-peak average
Injectable Testosterone Undecanoate
- Measure just before the next injection (trough level)
- Adjust dosing interval to maintain mid-normal range
Transdermal Gels
- Any time after 1 week of consistent use
- No specific timing relative to application needed once steady state achieved
Transdermal Patches
- 3-12 hours after patch application
Buccal Tablets
- Immediately before or after applying fresh system
Testosterone Pellets
- At the end of the dosing interval
Comprehensive Monitoring Beyond Testosterone
While the question focuses on testosterone testing, safety monitoring requires additional parameters at the same intervals 1:
At 3-6 months:
- Testosterone level (formulation-specific timing)
- Hematocrit (critical safety parameter—stop therapy if >54%)
- PSA and digital rectal exam (men ≥40 years with baseline PSA >0.6 ng/mL)
- Clinical symptom assessment
Annually thereafter:
- Same parameters as 3-6 month check
- Evaluate for symptom response and adverse effects
Critical Safety Thresholds
The guidelines emphasize that hematocrit monitoring is non-negotiable 1. If hematocrit exceeds 54%, therapy must be stopped until it decreases, the patient evaluated for hypoxia and sleep apnea, then therapy reinitiated at a reduced dose. This represents a significant morbidity risk that requires vigilant monitoring.
Common Pitfalls to Avoid
Timing errors are the most frequent mistake. Drawing testosterone levels at random times—particularly for injectable formulations—yields uninterpretable results. A level drawn 24 hours after a weekly injection will be artificially elevated, while one drawn just before the next injection may be inappropriately low, leading to unnecessary dose adjustments 2.
Inadequate monitoring frequency is widespread in clinical practice. One study found only 52.4% of men received testosterone testing in the 12 months after starting therapy 3. Another quality improvement project revealed only 4% of TRT patients received guideline-concordant annual monitoring 4.
Goal of Therapy
Therapy should aim to raise testosterone into the mid-normal range (approximately 450-600 ng/dL), not maximize levels 1, 5. Supraphysiologic dosing increases risks without additional benefit and makes safety monitoring more difficult.
The 2010 Endocrine Society guideline 1 represents the most recent and authoritative source, superseding the 2006 version 6 with refined monitoring intervals (3-6 months vs. 2-3 months initially) and updated safety thresholds.